119 related articles for article (PubMed ID: 23748247)
21. Identification of putative, stable binding regions through flexibility analysis of HIV-1 gp120.
Tan H; Rader AJ
Proteins; 2009 Mar; 74(4):881-94. PubMed ID: 18704932
[TBL] [Abstract][Full Text] [Related]
22. Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation.
Kong R; Tan JJ; Ma XH; Chen WZ; Wang CX
Biochim Biophys Acta; 2006 Apr; 1764(4):766-72. PubMed ID: 16455315
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
Guo Q; Ho HT; Dicker I; Fan L; Zhou N; Friborg J; Wang T; McAuliffe BV; Wang HG; Rose RE; Fang H; Scarnati HT; Langley DR; Meanwell NA; Abraham R; Colonno RJ; Lin PF
J Virol; 2003 Oct; 77(19):10528-36. PubMed ID: 12970437
[TBL] [Abstract][Full Text] [Related]
24. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
25. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
Wang HG; Williams RE; Lin PF
Curr Pharm Des; 2004; 10(15):1785-93. PubMed ID: 15180540
[TBL] [Abstract][Full Text] [Related]
26. Computational model of the HIV-1 subtype A V3 loop: study on the conformational mobility for structure-based anti-AIDS drug design.
Andrianov AM; Anishchenko IV
J Biomol Struct Dyn; 2009 Oct; 27(2):179-93. PubMed ID: 19583444
[TBL] [Abstract][Full Text] [Related]
27. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
28. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
[TBL] [Abstract][Full Text] [Related]
29. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
[TBL] [Abstract][Full Text] [Related]
30. The anti-HIV activity and mechanisms of action of pure compounds isolated from Rosa damascena.
Mahmood N; Piacente S; Pizza C; Burke A; Khan AI; Hay AJ
Biochem Biophys Res Commun; 1996 Dec; 229(1):73-9. PubMed ID: 8954085
[TBL] [Abstract][Full Text] [Related]
31. Progress in targeting HIV-1 entry.
Ryser HJ; Flückiger R
Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
[TBL] [Abstract][Full Text] [Related]
32. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
Kazmierski WM; Kenakin TP; Gudmundsson KS
Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
[TBL] [Abstract][Full Text] [Related]
33. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
34. Thioredoxin-1 and protein disulfide isomerase catalyze the reduction of similar disulfides in HIV gp120.
Reiser K; François KO; Schols D; Bergman T; Jörnvall H; Balzarini J; Karlsson A; Lundberg M
Int J Biochem Cell Biol; 2012 Mar; 44(3):556-62. PubMed ID: 22230366
[TBL] [Abstract][Full Text] [Related]
35. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
[TBL] [Abstract][Full Text] [Related]
36. Structural dynamics of V3 loop with different electrostatics: implications on co-receptor recognition: a molecular dynamics study of HIV gp120.
Chandramouli B; Chillemi G; Giombini E; Capobianchi MR; Rozera G; Desideri A
J Biomol Struct Dyn; 2013 Apr; 31(4):403-13. PubMed ID: 22876913
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gp120 V3 loop.
Andrianov AM; Anishchenko IV; Tuzikov AV
J Chem Inf Model; 2011 Oct; 51(10):2760-7. PubMed ID: 21888425
[TBL] [Abstract][Full Text] [Related]
38. Immunophilins and HIV-1 V3 loop for structure-based anti-AIDS drug design.
Andrianov AM
J Biomol Struct Dyn; 2009 Feb; 26(4):445-54. PubMed ID: 19108583
[TBL] [Abstract][Full Text] [Related]
39. Targeting HIV entry through interaction with envelope glycoprotein 120 (gp120): synthesis and antiviral evaluation of 1,3,5-triazines with aromatic amino acids.
Lozano V; Aguado L; Hoorelbeke B; Renders M; Camarasa MJ; Schols D; Balzarini J; San-Félix A; Pérez-Pérez MJ
J Med Chem; 2011 Aug; 54(15):5335-48. PubMed ID: 21749165
[TBL] [Abstract][Full Text] [Related]
40. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
Neurath AR; Strick N; Debnath AK
J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
